Weinblatt, M. E., Baranauskaite, A., Niebrzydowski, J., Dokoupilova, E., Zielinska, A., Jaworski, J., . . . Tseluyko, V. (2017). Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis. Arthritis Rheumatol.
Chicago Style aipamenaWeinblatt, Michael E., et al. "Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis." Arthritis Rheumatol 2017.
MLA aipamenaWeinblatt, Michael E., et al. "Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis." Arthritis Rheumatol 2017.
Kontuz: berrikusi erreferentzia hauek erabili aurretik.